Replies to post #125934 on Biotech Values

[acgood]

Quote:
If MNTA were to ink a comprehensive FoB deal with PFE, do you see any chance of MNTA being able to carve out rights to partner a substitutable Enbrel FoB with another party?
No, I don’t see any chance of that.

I agree...and that is okay. there really isn't a prospective partner (exception being MRK of those mentioned) that doesn't have a program of their own vulnerable to potential FOB competition.

Did your list mostly cut off due to scale/resources? Any of the next tier or other foreign firms have a compelling "pro" rationale?